Tag: Zepbound shortage

Following unprecedented demand, Eli Lilly resolved the widespread Zepbound shortage by investing billions in manufacturing expansions and strategic supply chain initiatives. This ultimately led the FDA to declare the tirzepatide supply issues resolved by December 2024.

Following widespread tirzepatide shortages that lasted into late 2024, the U.S. Food and Drug Administration (FDA) has ended the temporary period allowing compounding pharmacies to produce versions of the active ingredient in Zepbound. As of early 2025, compounded Zepbound is no longer widely or legally available, and patients who used these versions must transition to FDA-approved alternatives.